Melanoma Stage IV Clinical Trial
Official title:
A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | January 2027 |
Est. primary completion date | January 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years at the time of informed consent - Histologically confirmed diagnosis of melanoma. Any primary or unknown origin is permitted. - Melanoma must have a BRAFV600 mutation (using a CLIA-validated assay), either stage III (B/C/D) or Stage IV (AJCC 8th edition). - ECOG performance status = 2 - Adequate laboratory parameters as well: - a. Hemoglobin = 8 g/dL. - b. Platelets = 75 × 109/L; - c. AST and ALT = 2.5 × ULN; in participants with liver metastases = 5 × ULN; - d. Total bilirubin = 1.5 × ULN and < 2 mg/dL; OR total bilirubin >1.5 × ULN with indirect bilirubin < 1.5 × ULN; - e. Serum creatinine = 2.0 × ULN - Female participants of childbearing potential as described in protocol, must have a negative serum or urine ß-HCG test result. Female participants of childbearing potential must agree to use methods of contraception that are highly effective or acceptable, as described in Section 4.3.1. Participants must agree to not use hormonal contraceptives, as encorafenib can result in decreased concentration and loss of efficacy. Male participants must agree to use methods of contraception that are highly effective or acceptable per protocol. Exclusion Criteria: - Participants may have received prior therapy with BRAF and/or a MEK inhibitor if it was completed at least 6 months prior to study enrollment. Patients who had prior disease progression while on BRAF/MEK inhibitor therapy are not eligible. (Progression after stopping treatment is permitted.) Participants may have received prior therapy an anti-PD-1/PD-L1 or CTLA-4 inhibitor. - Participants must not have had adverse events related to encorafenib and/or binimetinib specifically, that required discontinuation of one or both drugs due to toxicity. - Participants who have had major surgery or radiotherapy = 14 days prior to start of study treatment or who have not recovered from side effects of such procedure. - Participants must be willing to avoid consuming grapefruit, pomegranates, star fruits, Seville oranges or products containing the juice during the study while they are taking encorafenib/binimetinib. - Uncontrolled or symptomatic brain metastases or leptomeningeal carcinomatosis that are not stable, require steroids, are potentially life-threatening or have required radiation within 28 days prior to starting study drug. Patients with previously treated brain metastases may participate provided they are stable (e.g.,without evidence of progression by radiographic imaging for at least 28 days before the first dose of study treatment and neurologic symptoms have returned to baseline). - Impaired cardiovascular function as below: - a. Congestive heart failure requiring treatment (New York Heart Association Grade = 3); - b. presence of uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia - c. Baseline QTcF interval = 500 ms. - Known history of retinal vein occlusion (RVO) - Current use of a prohibited medication (including herbal medications, supplements, or foods), as described in protocol, or use of a prohibited medication = 1 week prior to the start of study treatment. - Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. - Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 90 days prior to randomization. - Participants with a known history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with HCV infection who are currently on treatment must have an undetectable HCV viral load prior to randomization. - Pregnancy or breast feeding. |
Country | Name | City | State |
---|---|---|---|
United States | Moffitt Cancer Center | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
H. Lee Moffitt Cancer Center and Research Institute | Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Disease Relapse | Investigators will estimate the rate of disease relapse after neoadjuvant therapy based on pathologic complete response status and postoperative adjuvant therapy within each arm. | After surgery up to 24 weeks | |
Secondary | Relapse Free Survival | Relapse free survival is defined as time from surgery until disease relapse | After surgery up to 24 weeks | |
Secondary | Rate of Pathologic Complete Response | Investigators will measure the rate of pathologic complete response after surgery. | At 26 weeks | |
Secondary | Rate of Non-Pathologic Complete Response | Investigators will measure the rate of non-pathologic complete response after surgery. | At 26 weeks | |
Secondary | Overall Response Rate | Overall response rate will be measured after neoadjuvant therapy (for participants who have measurable disease per RECIST 1.1 at start of neoadjuvant therapy). | Up to 26 weeks | |
Secondary | Overall Survival | Overall survival will be measured from time of surgery to death from any cause. | After surgery, up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04330430 -
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease
|
Phase 2 | |
Withdrawn |
NCT04007588 -
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
|
Phase 2 | |
Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Recruiting |
NCT04562129 -
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
|
Phase 2 | |
Recruiting |
NCT04990726 -
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
|
||
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05370807 -
A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
|
Phase 2 | |
Recruiting |
NCT04045691 -
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
|
||
Not yet recruiting |
NCT05070221 -
Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis
|
Phase 1 | |
Not yet recruiting |
NCT05068453 -
Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis
|
Phase 1 | |
Recruiting |
NCT03353402 -
Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy
|
Phase 1 | |
Recruiting |
NCT04513028 -
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
|
N/A | |
Recruiting |
NCT05598853 -
Intrathecal Double Checkpoint Inhibition
|
Phase 1 | |
Recruiting |
NCT04521075 -
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT06425926 -
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03153085 -
A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma
|
Phase 2 | |
Recruiting |
NCT03991130 -
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04526899 -
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
|
Phase 2 | |
Recruiting |
NCT06319196 -
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
|
Phase 2 |